What Happened?
Shares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial results from peers Merck and Moderna for an mRNA cancer treatment lifted sentiment across the pharmaceutical sector.
The two companies reported that their mRNA cancer treatment met its primary goal in a Phase 3 clinical trial when combined with the drug Keytruda. This study, which included 1,137 patients, demonstrated a statistically significant improvement in recurrence-free survival compared to using Keytruda by itself.
The shares closed the day at $28.23, up 3.7% from the previous close.
Is now the time to buy Pfizer? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Pfizer’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 7.2% on the news that the company announced a landmark agreement with the U.S. government aimed at lowering prescription drug prices for American patients.
The historic pact includes several key measures. Pfizer will voluntarily align prices for its drugs in Medicaid programs with those in other developed countries, a policy referred to as 'most-favored-nation' pricing.
Additionally, the company will offer medicines directly to consumers at significant discounts—averaging 50%—through a new government-operated website, TrumpRx.gov. In return for these pricing concessions and a commitment to invest $70 billion in U.S. research and manufacturing, Pfizer secured a three-year grace period from potential tariffs. The market reacted positively, as the voluntary agreement is seen as a way for the pharmaceutical industry to avoid stricter legislation and removes a major policy uncertainty that has weighed on the sector.
Pfizer is up 12% since the beginning of the year, and at $28.19 per share, it is trading close to its 52-week high of $28.55 from March 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Pfizer’s shares 5 years ago would now be looking at only $577.66.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.